are people dying from semaglutide Weight loss jabs: Two deaths reported to drug watchdog What Ozempic & Weight Loss

The published literature on GLP-1 agonists in paediatrics is predominantly from paediatric patients 10 to 18 years old and concerns are similar to those reported in adults

Users should report any unusual symptom or side effect to the healthcare provider wisely

This guide walks through how a typical dosing schedule is structured, why the increases happen slowly, and what patients should know before starting treatment

It is often well-tolerated in moderate doses but may have a mild laxative effect, which could be problematic for GLP-1 users already experiencing diarrhea or gastrointestinal upset

Semaglutide GLP-1 receptor agonist analogue used extensively in obesity and metabolic syndrome preclinical research

BMJ 342 , d1165 (2011)